1424337-30-3

Upstream product

• 956234-46-1 (R)-2-Bromo-1-(2,2-dimethyl-4H-benzo[1,3]dioxin-6-yl)ethanol 
• 102293-80-1 2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethanone 
• 62932-94-9 2-bromo-1-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethanone 
• 956234-47-2 (2-bromo-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)ethoxy)(tert-butyl)dimethylsilane 
• 1424337-26-7 3-(6-aminohexyloxy)-N-(3,5-dichloropyridin-4-yl)-4-methoxybenzamide 
• 115787-50-3 5-(2-bromoacetyl)-2-hydroxybenzaldehyde 
• 1424337-23-4 3-(6-(1,3-dioxoisoindolin-2-yl)hexyloxy)-4-methoxybenzoic acid 
• 1424337-19-8 3-(6-(1,3-dioxoisoindolin-2-yl)hexyloxy)-4-methoxybenzaldehyde 
• 90-02-8 salicylaldehyde 
• 24566-79-8 2-(6-bromohexyl)isoindole-1,3-dione 
• 629-03-8 1 ,6-dibromohexane 

Downstream Products

• 1424337-12-1 C₂₈H₃₃Cl₂N₃O₆ 

Relevant academic research and scientific papers

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

A novel class of dual pharmacology bronchodilators targeting both β2-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better β2-adrenoceptor agonist activities (pEC50 = 8.47-9.20) than the reference compound salmeterol (pEC50 = 8.3) and good inhibitory activity on PDE4B2 (IC 50 = 0.235-1.093 μM).